Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Meta Expands AI Training With Employee Activity Tracking Tools 
CAMBRIDGE, Mass., March 29, 2017 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a company overview at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 9:20 a.m. ET in New York City.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.
About Genocea Biosciences Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLASTM, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea’s pipeline includes GEN-003, a novel T cell-enabled immunotherapy for genital herpes currently in Phase 2 clinical development, and earlier-stage investments in immuno-oncology. For more information, please visit the company's website at www.genocea.com.
For media: Jennifer LaVin O: 617-715-6687 [email protected] For investors: Jonathan Poole O: 617-876-8191 [email protected]
